Anzeige
Mehr »
Donnerstag, 31.07.2025 - Börsentäglich über 12.000 News
Der KI-Energiekollaps: Uran auf kritischem Kurs - und Foremost Clean Energy entflammt den Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
511 Leser
Artikel bewerten:
(2)

Tracelink, Inc.: TraceLink's 2023 Success: Expanded Digitalization Capabilities and Growing Adoption of New Supply Chain Solutions

BOSTON, Feb. 5, 2024 /PRNewswire/ -- TraceLink, the world's largest digital network platform for healthcare and life sciences, expanded its digitalization capabilities in 2023, leading to an annual increase of more than 300 new customers. Utilizing the industry's largest integrated digital network of over 290,000 entities, TraceLink is working to revolutionize the way businesses orchestrate the digital journeys of products, processes, and partners that span the end-to-end supply chain, resulting in the following 2023 achievements:


Customer Growth: Surpassing 1,600 total customers, an increase of 23%, a testament to the market's confidence in TraceLink's unique supply chain digitalization model. These 1,600+ customers' supply chain activities operate in over 100 countries globally.

Solution Adoption: 50+ new clients in 2023 selected TraceLink's cutting-edge solutions in orchestration intelligence, partner orchestration, and process orchestration, demonstrating broad industry demand for end-to-end supply chain digitalization capabilities.

Successful Implementations: 510 customer implementation projects were deployed on the TraceLink network in 2023, demonstrating the effectiveness of TraceLink's unique Integrate-Once partner integration and solution delivery model.

"Our team's relentless focus on customer enablement and success, and our ability to meet rapidly changing supply chain demands through our proven network integration capabilities, have been key drivers of our growth this year. Eclipsing more than 1,600 total customers in 2023 is a clear indication that our vision and maturing set of product, partner, and process orchestration capabilities is resonating with the market," said Shabbir Dahod, President & CEO, TraceLink.

The growth was fueled by the introduction of a range of new solutions aimed at tackling the industry's most intricate multienterprise challenges:

  • Product Availability Intelligence (PAI): Designed to enhance product availability and minimize shortages by leveraging advanced analytics and real-time data to predict them 90 days in advance.
  • Multienterprise Information Network Tower (MINT): Enabling 100% partner integration, at an affordable cost, to provide a comprehensive view across the supply chain, facilitating better decision-making through increased visibility and collaboration.
  • Supply Chain Work Management for Compliance Exceptions (SCWM): Facilitating the management and resolution of compliance exceptions efficiently, ensuring regulatory adherence while maintaining supply chain integrity.
  • Compliance Solutions for Emerging Markets: Supporting regulatory requirements in Kazakhstan, Kyrgyzstan, and other emerging markets, aiding businesses in navigating complex compliance landscapes.
  • Expanded DSCSA Capabilities: Streamlining compliance with the Drug Supply Chain Security Act (DSCSA), improving traceability and security in pharmaceutical supply chains while providing operational efficiency.

These new offerings underscore TraceLink's unwavering commitment to solving the most pressing challenges of supply chain orchestration. TraceLink's efforts in digitalizing the supply chain continue to set the industry standard, demonstrating how strategic innovation can lead to tangible improvements in efficiency, compliance, and collaboration across the global healthcare and life sciences sector.

For more information, please visit www.tracelink.com.

About TraceLink Inc.:
TraceLink Inc. is the leading digital network platform company, enabling end-to-end product orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of pharmaceuticals, ensuring that every patient gets the medicines they need when needed, safely and securely. For more information, visit www.tracelink.com.

Contact:
Erica Burns
edurham@tracelink.com

Logo - https://mma.prnewswire.com/media/1004729/TraceLink_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/tracelinks-2023-success-expanded-digitalization-capabilities-and-growing-adoption-of-new-supply-chain-solutions-302053726.html

© 2024 PR Newswire
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.